Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform. The Company aims to utilize the body’s own machinery – the T-cell to target and destroy cancer cells by using engineered, increased affinity T-cell receptors, or TCRs, as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is a SPEAR T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has demonstrated signs of efficacy and tolerability in Phase I/II trials in solid tumors and in hematologic cancer types, including synovial sarcoma, multiple myeloma, NSCLC and MRCLS. Adaptimmune recently reported interim data in synovial sarcoma, with median PFS data of 18 months and an overall response rate of 50% in cohort one. In addition, Adaptimmune has a number of proprietary programs including SPEAR T-cell therapies targeting the MAGE-A10 (Phase I) and alpha fetoprotein (AFP) cancer antigens (Phase I ready), and a further SPEAR T-cell therapy targeting the MAGE-A4 cancer antigen (Phase I ready). The Company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs.